The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma

MLA

Teruaki Akaogi, et al. “The Response to Second-Line Induction with Bortezomib and Dexamethasone Is Predictive of Long-Term Outcomes Prior to High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma.” Internal Medicine (Tokyo, Japan), vol. 52, no. 9, May 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a989941de15274b17a0b2f5cdb11f1fc&authtype=sso&custid=ns315887.

APA

Teruaki Akaogi, Eri Kawata-Iida, Chihiro Shimazaki, Mayumi Hatsuse, Yosuke Matsumoto, Nobuhiko Uoshima, Satoshi Murakami, Ryoichi Takahashi, Shin-ichi Fuchida, Shigeo Horiike, Hitoji Uchiyama, Mitsushige Nakao, Tsutomu Kobayashi, Yutaka Kobayashi, Hiroto Kaneko, Masafumi Taniwaki, Yasuhiko Tsutsumi, Junya Kuroda, Akira Okano, … Toshiki Iwai. (2013). The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Internal Medicine (Tokyo, Japan), 52(9).

Chicago

Teruaki Akaogi, Eri Kawata-Iida, Chihiro Shimazaki, Mayumi Hatsuse, Yosuke Matsumoto, Nobuhiko Uoshima, Satoshi Murakami, et al. 2013. “The Response to Second-Line Induction with Bortezomib and Dexamethasone Is Predictive of Long-Term Outcomes Prior to High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma.” Internal Medicine (Tokyo, Japan) 52 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a989941de15274b17a0b2f5cdb11f1fc&authtype=sso&custid=ns315887.